Xianping Lu

Chairman, General Manager and Chief Scientist, Shenzhen Chipscreen Biosciences Company Limited


Xianping Lu is the Chairman, General Manager and Chief Scientist of Shenzhen Chipscreen Biosciences Company Limited. He graduated from Sichuan University with a Bachelor's degree in Biochemistry, and from Peking Union Medical College/the Chinese Academy of Medical Sciences with a Ph.D. in Science. Dr. Lu worked as a postdoctoral researcher at the University of California, San Diego (UCSD) from January 1989 to June 1994. From June 1994 to April 1998, he participated in the founding of Maxia Pharmaceutical Company and Galderma Research Biotechnology Company. From May 1998 to September 2000, he served as Director of the Research Unit under the North American Research and Development Center at Galderma Research Biotechnology Company in the United States. From October 2000 to October 2001, he was a senior visiting scholar of the State Key Laboratory of Biomembrane and Membrane Bioengineering at Tsinghua University. 

Dr. Lu has extensive experience in the R&D and management of global drugs, especially in the areas of molecular medicine, cancer, neuroendocrinology, immunology, metabolism and skin diseases. He is also in charge of a number of major scientific and technological research projects, such as the National High-tech R&D Program (863 Program). He has published more than 100 peer-reviewed papers in prestigious journals including Nature, Science, Nature Science and The Lancet Oncology. He is the lead inventor of over 100 patented-inventions in areas of small molecule therapeutics.

Dr. Lu’s achievements have been widely recognized and won him and his team many awards, such as third prize in the Ministry of Health's Medical Science Progress Award in 1989, and first prize in the State Science and Technology Prizes in 2013. In 2015, he was among the top 10 innovators in China and the US by Forbes. In 2016, he was named Person of the Year by Scientific Chinese. He also received the Gold Award for China Patent, jointly presented by the State Intellectual Property Office World Intellectual Property Organization in 2017, and the China Pharmaceutical Development Award for Outstanding Achievement in Innovative Drugs by Chinese Pharmaceutical Association in the same year.